Literature DB >> 21385178

Increased availability of angiotensin AT 1 receptors leads to sustained arterial constriction to angiotensin II in diabetes - role for Rho-kinase activation.

Zsolt Bagi1, Attila Feher, James Cassuto, Komala Akula, Nazar Labinskyy, Gabor Kaley, Akos Koller.   

Abstract

BACKGROUND AND
PURPOSE: Antagonists of angiotensin AT(1) receptors elicit beneficial vascular effects in diabetes mellitus. We hypothesized that diabetes induces sustained availability of AT(1) receptors, causing enhanced arterial constriction to angiotensin II. EXPERIMENTAL APPROACH: To assess functional availability of AT(1) receptors, constrictions to successive applications of angiotensin II were measured in isolated skeletal muscle resistance arteries (∼150 µm) of Zucker diabetic fatty (ZDF) rats and of their controls (+/Fa), exposed acutely to high glucose concentrations (HG, 25 mM, 1 h). AT(1) receptors on cell membrane surface were measured by immunofluorescence. KEY
RESULTS: Angiotensin II-induced constrictions to first applications were greater in arteries of ZDF rats (maximum: 82 ± 3% original diameter) than in those from +/Fa rats (61 ± 5%). Constrictions to repeated angiotensin II administration were decreased in +/Fa arteries (20 ± 6%), but were maintained in ZDF arteries (67 ± 4%) and in +/Fa arteries vessels exposed to HG (65 ± 6%). In ZDF arteries and in HG-exposed +/Fa arteries, Rho-kinase activities were enhanced. The Rho-kinase inhibitor, Y27632 inhibited sustained constrictions to angiotensin II in ZDF arteries and in +/Fa arteries exposed to HG. Levels of surface AT(1) receptors on cultured vascular smooth muscle cells (VSMCs) were decreased by angiotensin II but were maintained in VSMCs exposed to HG. In VSMCs exposed to HG and treated with Y27632, angiotensin II decreased surface AT(1) receptors. CONCLUSIONS AND IMPLICATIONS: In diabetes, elevated glucose concentrations activate Rho-kinase which inhibits internalization or facilitates recycling of AT(1) receptors, leading to increased functional availability of AT(1) receptors and sustained angiotensin II-induced arterial constriction.
© 2011 The Authors. British Journal of Pharmacology © 2011 The British Pharmacological Society.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21385178      PMCID: PMC3130951          DOI: 10.1111/j.1476-5381.2011.01307.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  41 in total

1.  Coronary arteriolar vasoconstriction to angiotensin II is augmented in prediabetic metabolic syndrome via activation of AT1 receptors.

Authors:  Cuihua Zhang; Jarrod D Knudson; Srinath Setty; Alberto Araiza; U Deniz Dincer; Lih Kuo; Johnathan D Tune
Journal:  Am J Physiol Heart Circ Physiol       Date:  2005-01-14       Impact factor: 4.733

2.  Differential regulation of ERK1/2 and p38(MAPK) by components of the Rho signaling pathway during sphingosine-1-phosphate-induced smooth muscle cell migration.

Authors:  Irfan I Galaria; Allison J Fegley; Suzanne M Nicholl; Elisa Roztocil; Mark G Davies
Journal:  J Surg Res       Date:  2004-12       Impact factor: 2.192

Review 3.  Rho GTPases, statins, and nitric oxide.

Authors:  Yoshiyuki Rikitake; James K Liao
Journal:  Circ Res       Date:  2005-12-09       Impact factor: 17.367

Review 4.  G protein-coupled receptors. III. New roles for receptor kinases and beta-arrestins in receptor signaling and desensitization.

Authors:  R J Lefkowitz
Journal:  J Biol Chem       Date:  1998-07-24       Impact factor: 5.157

5.  Enhanced role for RhoA-associated kinase in adrenergic-mediated vasoconstriction in gracilis arteries from obese Zucker rats.

Authors:  Jay S Naik; Lusha Xiang; Robert L Hester
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2005-09-01       Impact factor: 3.619

6.  COX-2 up-regulation and vascular smooth muscle contractile hyperreactivity in spontaneous diabetic db/db mice.

Authors:  Zhenheng Guo; Wen Su; Shannon Allen; Huan Pang; Alan Daugherty; Eric Smart; Ming C Gong
Journal:  Cardiovasc Res       Date:  2005-09-01       Impact factor: 10.787

7.  AT1 receptors and L-type calcium channels: functional coupling in supersensitivity to angiotensin II in diabetic rats.

Authors:  K H S Arun; C L Kaul; P Ramarao
Journal:  Cardiovasc Res       Date:  2005-02-01       Impact factor: 10.787

8.  Type 2 diabetic mice have increased arteriolar tone and blood pressure: enhanced release of COX-2-derived constrictor prostaglandins.

Authors:  Zsolt Bagi; Nora Erdei; Attila Toth; Wei Li; Thomas H Hintze; Akos Koller; Gabor Kaley
Journal:  Arterioscler Thromb Vasc Biol       Date:  2005-06-09       Impact factor: 8.311

9.  Endothelial dysfunction and hypercontractility of vascular myocytes are ameliorated by fluvastatin in obese Zucker rats.

Authors:  Hiroaki Nishimatsu; Etsu Suzuki; Hiroshi Satonaka; Ryo Takeda; Masao Omata; Toshiro Fujita; Ryozo Nagai; Tadaichi Kitamura; Yasunobu Hirata
Journal:  Am J Physiol Heart Circ Physiol       Date:  2004-11-18       Impact factor: 4.733

10.  Endothelin and prostaglandin H2 enhance arteriolar myogenic tone in hypertension.

Authors:  A Huang; A Koller
Journal:  Hypertension       Date:  1997-11       Impact factor: 10.190

View more
  9 in total

1.  Direct effects of Rho-kinase inhibitor on pial microvessels in rabbits.

Authors:  Masakazu Kotoda; Tadahiko Ishiyama; Noriyuki Shintani; Takashi Matsukawa
Journal:  J Anesth       Date:  2014-08-24       Impact factor: 2.078

2.  Gestational exposure to elevated testosterone levels induces hypertension via heightened vascular angiotensin II type 1 receptor signaling in rats.

Authors:  Vijayakumar Chinnathambi; Amar S More; Gary D Hankins; Chandra Yallampalli; Kunju Sathishkumar
Journal:  Biol Reprod       Date:  2014-05-22       Impact factor: 4.285

Review 3.  ESC Working Group on Coronary Pathophysiology and Microcirculation position paper on 'coronary microvascular dysfunction in cardiovascular disease'.

Authors:  Teresa Padro; Olivia Manfrini; Raffaele Bugiardini; John Canty; Edina Cenko; Giuseppe De Luca; Dirk J Duncker; Etto C Eringa; Akos Koller; Dimitris Tousoulis; Danijela Trifunovic; Marija Vavlukis; Cor de Wit; Lina Badimon
Journal:  Cardiovasc Res       Date:  2020-03-01       Impact factor: 10.787

4.  Caveolin-1 prevents sustained angiotensin II-induced resistance artery constriction and obesity-induced high blood pressure.

Authors:  Istvan Czikora; Attila Feher; Rudolf Lucas; David J R Fulton; Zsolt Bagi
Journal:  Am J Physiol Heart Circ Physiol       Date:  2014-12-19       Impact factor: 4.733

5.  Rho-kinase and the nitric oxide pathway modulate basilar arterial reactivity to acetylcholine and angiotensin II in streptozotocin-induced diabetic mice.

Authors:  Md Zahorul Islam; Cuong Van Dao; Atsushi Miyamoto; Mitsuya Shiraishi
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2017-06-27       Impact factor: 3.000

Review 6.  Endothelial regulation of coronary microcirculation in health and cardiometabolic diseases.

Authors:  Akos Koller; Marta Balasko; Zsolt Bagi
Journal:  Intern Emerg Med       Date:  2013-04       Impact factor: 3.397

7.  Treatment with the cytochrome P450 ω-hydroxylase inhibitor HET0016 attenuates cerebrovascular inflammation, oxidative stress and improves vasomotor function in spontaneously hypertensive rats.

Authors:  Peter Toth; Anna Csiszar; Danuta Sosnowska; Zsuzsanna Tucsek; Peter Cseplo; Zsolt Springo; Stefano Tarantini; William E Sonntag; Zoltan Ungvari; Akos Koller
Journal:  Br J Pharmacol       Date:  2013-04       Impact factor: 8.739

Review 8.  Mechanobiology of Microvascular Function and Structure in Health and Disease: Focus on the Coronary Circulation.

Authors:  Maarten M Brandt; Caroline Cheng; Daphne Merkus; Dirk J Duncker; Oana Sorop
Journal:  Front Physiol       Date:  2021-12-23       Impact factor: 4.566

9.  Adiponectin Attenuates Angiotensin II-Induced Vascular Smooth Muscle Cell Remodeling through Nitric Oxide and the RhoA/ROCK Pathway.

Authors:  Wared Nour-Eldine; Crystal M Ghantous; Kazem Zibara; Leila Dib; Hawraa Issaa; Hana A Itani; Nabil El-Zein; Asad Zeidan
Journal:  Front Pharmacol       Date:  2016-04-07       Impact factor: 5.810

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.